Abstract: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.

Abstract: The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them.

Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, or a pharmaceutically acceptable salt thereof, that can be administered to a human subject in need thereof. The disclosure also provides pharmaceutical compositions for treatment of orthostatic hypotension that can be administered once or twice a day.

Abstract: The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.

Abstract: Oral pharmaceutical compositions which include an extended-release multi-particulate comprising an effective amount of droxidopa, or a pharmaceutically acceptable salt thereof, and a release-controlling agent are disclosed. The compositions can be in the form of a ready-to-use suspension or a solid composition suitable for reconstitution with a liquid vehicle. Methods of making and using the compositions are also disclosed.

Abstract: A pharmaceutical composition is disclosed. The composition comprises a core comprising an active substance or a salt thereof; a separating layer comprising at least one sugar; and a functional layer comprising at least one pharmaceutically acceptable polymer, wherein the composition is resistant to dose dumping in presence of alcohol.

Abstract: Disclosed herein is a stabilized sustained release pharmaceutical composition of bupropion hydrochloride and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of uncoated fine bupropion hydrochloride and pharmaceutically acceptable adjuvants, and wherein the composition is free of an acidic stabilizer and contains less than about 0.3% by weight of m-chlorobenzoic acid.

Abstract: A delayed extended release pharmaceutical composition includes a compressed core containing an effective amount of bupropion or its pharmaceutically acceptable salt, a water-attractant polymer. The core is preferably devoid of a stabilizer. The core is surrounded by an extended release layer, which is free of plasticizer and pore-forming agent. The extended release layer is surrounded by a delayed release layer. Alternating coats of extended release layer and delayed release layer may follow. A preferred extended release layer includes ethylcellulose and hydroxypropyl cellulose or hydroxypropyl methylcellulose and a preferred delayed release layer includes methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate, lactose and a combination of triethyl citrate and polyethylene glycol and talc. A method of preparing the delayed extended release bupropion hydrochloride containing pharmaceutical composition is also disclosed.

Abstract: A clock circuit. The clock circuit includes a phase detector and an output unit. The phase detector is coupled to receive a reference clock signal and an output clock signal, and is configured to provide a phase signal indicative of a phase difference between the reference and output clock signals. The output unit is configured to provide the output clock signal, and is coupled to a first supply voltage node and a second supply voltage node. The output unit includes a biasing circuit and a voltage-controlled element. The biasing circuit is coupled to receive a control voltage based on the phase signal and is configured to generate a bias voltage based on the received control voltage. The voltage-controlled element is configured to adjust a parameter of the output clock signal based on the bias voltage. A supply-independent output clock is attained using this configuration.

Abstract: A clock circuit. The clock circuit includes a phase detector and an output unit. The phase detector is coupled to receive a reference clock signal and an output clock signal, and is configured to provide a phase signal indicative of a phase difference between the reference and output clock signals. The output unit is configured to provide the output clock signal, and is coupled to a first supply voltage node and a second supply voltage node. The output unit includes a biasing circuit and a voltage-controlled element. The biasing circuit is coupled to receive a control voltage based on the phase signal and is configured to generate a bias voltage based on the received control voltage. The voltage-controlled element is configured to adjust a parameter of the output clock signal based on the bias voltage. A supply-independent output clock is attained using this configuration.